As previously reported, Janney Capital downgraded to Neutral from Buy. The firm downgraded shares based on bird-flu concerns following reports of a second human infection in China of the relatively newer H7N9 strain. The firm expects media attention in China to increase, which could pressure the same-store-sales recovery for the next few quarters. Price target is $65.
- Investment & Company Information